Join our daily newsletter At The Bell to receive exclusive market insights
- Cann Global (CGB) has entered a binding agreement with Western Sydney University’s NICM Health Research Institute
- The company is currently evaluating the efficacy of a unique strain of medicinal cannabis to slow the progression of multiple sclerosis (MS)
- Under the agreement, the parties will design a clinical trial protocol for the purpose of undertaking human clinical trials in Australia
- On the market today, Cann is up 21.4 per cent and is trading at 0.9 cents per share
Cann Global (CGB) has entered a binding agreement with Western Sydney University’s NICM Health Research Institute.
The company is currently evaluating the efficacy of a unique strain of medicinal cannabis to slow the progression of multiple sclerosis (MS).
Under the agreement, the parties will design a clinical trial protocol for the purpose of undertaking human clinical trials in Australia.
Last year, Cann saw successful research results in Israel, where research led by Dr Dedi Meiri found that a unique cannabis strain in mice trials stopped the progression of MS and, in some cases, significantly reversed the damage caused by MS.
In February, Cann Global announced that the human clinical trials for this research would be continued in Australia, as clinical data and results are recognised worldwide due to the high standard of research.
NICM Health Research Institute is Australia’s leader in integrative and complementary medicine research and policy.
“Cann will update the market with the expected timetable for implementation
of the clinical trials once the protocol has been designed,” Cann told the market today.
On the market today, Cann is up 21.4 per cent and is trading at 0.9 cents per share at 11:27 am AEST.
